NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission....
People with relapsed or refractory diffuse large B-cell lymphoma who cannot have an
autologous stem cell transplant usually have polatuzumab vedotin plus rituximab and
bendamustine.
The clinical evidence is from a small study that did not directly compare tafasitamab plus
lenalidomide with any other trea...
Nanchal, Rahul;
Subramanian, Ram;
Alhazzani, Waleed;
Dionne, Joanna C;
Peppard, William J;
Singbartl, Kai;
Truwit, Jonathon;
Al-Khafaji, Ali H;
Killian, Alley J;
Alquraini, Mustafa;
Alshammari, Khalil;
Alshamsi, Fayez;
Belley-Cote, Emilie;
Cartin-Ceba, Rodrigo;
Hollenberg, Steven M;
Galusca, Dragos M;
Huang, David T;
Hyzy, Robert C;
Junek, Mats;
Kandiah, Prem;
Kumar, Gagan;
Morgan, Rebecca L;
Morris, Peter E;
Olson, Jody C;
Sieracki, Rita;
Steadman, Randolph;
Taylor, Beth;
Karvellas, Constantine J.
To develop evidence-based recommendations for clinicians caring for adults with acute liver failure (ALF) or acute on chronic liver failure (ACLF) in the ICU. The guideline panel comprised 27 members with expertise in aspects of care of the critically ill patient with liver failure or methodology. We adh...
Bell, Alan D;
MacCallum, Caroline;
Margolese, Shari;
Walsh, Zach;
Wright, Patrick;
Daeninck, Paul J;
Mandarino, Enrico;
Lacasse, Gary;
Deol, Jagpaul Kaur;
Freitas, Lauren de;
St. Pierre, Michelle;
Belle-Isle, Lynne;
Gagnon, Marilou;
Bevan, Sian;
Sanchez, Tatiana;
Arlt, Stephanie;
Monahan-Ellison, Max;
O'Hara, James;
Boivin, Michael;
Costiniuk, Cecilia.
One in five individuals live with chronic pain globally, which often co-occurs with sleep problems, anxiety, depression, and substance use disorders. Although these conditions are commonly managed with cannabinoid-based medicines (CBM), health care providers report lack of information on the risks, benef...
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Commercial availability
The Wegovy brand of semaglutide is not commercially available yet....
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Commercial arrangement
There is a simple discount patient access scheme for eptinezumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact United...
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
Commercial arrangement
There is a simple discount patient access scheme for cannabidiol. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS orga...
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.
Commercial arrangement
There is a simple discount patient access scheme for polatuzumab vedotin. NHS organisations can get ...
Sandbrink, Friedhelm;
Murphy, Jennifer L;
Johansson, Melanie;
Olson, Juli L;
Edens, Ellen;
Clinton-Lont, Jamie;
Sall, James;
Spevak, Christopher;
Brown, Nicole;
Guinta, Raquel;
Macedo, Franz;
Nazario, Mitchell;
Pangarkar, Sanjog;
Preston, Samuel;
Prince, Matthew;
Real, Donna Endsley;
Riegleman, David;
Steil, Evan.
In May 2022, leadership within the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the use of opioids when managing chronic pain. This synopsis summarizes the recommendations that the authors believe are the most important to ...
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.
Commercial arrangement
There is a simple discount patient access scheme for vutrisiran. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NH...
